How to Take Peptides: Routes, Timing, and Reported Practice
How are most peptide drugs taken? Every approved GLP-1 label specifies subcutaneous injection into the abdomen, thigh or upper arm. One molecule, semaglutide, also comes as a tablet.
What timing do the labels specify? The Ozempic label specifies the same day each week, any time of day, with or without meals, and a 5 day window for a missed dose (approved label).
Is there a studied way to take research peptides such as BPC-157? No. Community practice reports 250 to 500 mcg daily (community practice, no trial). No human trial has tested that range or any other.
Where does technique advice come from? Almost entirely from insulin studies. No technique trial used any other peptide.
Peptides Vietnam read 21 PubMed records and 9 manufacturer labels for this cluster, and says so where the evidence runs out.
What does the evidence actually cover?
The short answer is approved labels, insulin studies and reported community practice, because no technique trial has used a peptide other than insulin.
Searches for trials of rotation, needle length, angle and skin fold returned zero studies using any drug besides insulin. One needle trial's authors state this limit themselves and call for trials in GLP-1 users (PMID 20429832). Technique knowledge is transferred by analogy. Competitors present it as settled. It is not.
Which routes do the approved labels specify?
Subcutaneous injection is the labelled route for every approved GLP-1, and semaglutide is the one molecule that also has an oral form.
All four GLP-1 labels name the same three regions: abdomen, thigh and upper arm. Mounjaro adds that the back of the upper arm is to be injected by another person.
No label found specifies an angle or a gauge.
Absorption is not one number either. The labels state subcutaneous bioavailability (approved label):
| Molecule | Subcutaneous bioavailability |
|---|---|
| for semaglutide | of 89% |
| for tirzepatide | 80% |
| for dulaglutide as the dose rises | 65% falling to 47% |
Oral semaglutide shows the cost of the other route. The label gives about 0.4% to 2% oral bioavailability and states the tablet and injection are not substitutable milligram for milligram.
The tablet carries a strict ritual: empty stomach, no more than 4 ounces of water, swallowed whole, 30 minutes before food, drink or other oral medicines (approved label). Full comparison: oral versus injectable peptides.
What timing and titration do the labels specify?
The labels specify weekly dosing with wide timing flexibility, plus stepwise titration for stomach tolerability rather than potency.
The approved labels specify:
Ozempic once weekly on the same day each week, at any time of day, with or without meals; a missed dose may be administered within 5 days (approved label).
Wegovy: the time of day and the injection site can be changed without a dosage modification (approved label).
Disclaimer: these are label statements for specific approved products, not guidance that transfers to any other peptide.
Titration follows the same pattern.
The approved labels specify:
- Ozempic 0.25 mg once weekly for 4 weeks, then 0.5 mg (approved label).
- Wegovy injection 0.25 mg once weekly for 4 weeks, titrating every 4 weeks toward a usual maintenance of 2.4 mg (approved label).
- The Mounjaro label specifies an initial 2.5 mg once weekly (approved label).
- The Trulicity label specifies an initial 0.75 mg once weekly (approved label).
Disclaimer: the Ozempic label states the escalation exists to reduce gastrointestinal adverse reactions, so the opening amount is a tolerability step, not a potency statement. More on scheduling sits in the best time to inject FAQ.
Why do unit mix-ups cause ten-fold overdoses?
Because vials and syringes remove the metered pen, and one product gets described in three different unit systems.
The anchor comes from the FDA approved Humalog label: U-100 insulin contains 100 units per millilitre, so one unit on a U-100 syringe equals 0.01 mL.
The unit scale belongs to a syringe matched to one product concentration, not a universal volume measure.
A poison control case series documents the result (PMID 37392810). Three patients received compounded semaglutide in vials with syringes instead of a metered pen, and the product was described in millilitres, units and milligrams. Two patients self administered ten-fold overdoses.
Three cases establish a mechanism, not a frequency. Syringe math: insulin syringe sizes for peptides. Product vetting: fake GLP-1 products in Vietnam.
What does community practice report for research peptides?
One compound has a widely repeated range, recorded here as practice with no trial behind it.
For BPC-157 and TB-500 there is no approved label in any market, so nothing label-like can be cited. Community practice reports:
- BPC-157 at 250 to 500 mcg daily, often near the injury site (community practice).
- No trial has tested that range or any other in humans.
Disclaimer: No clinical trial has established that or any other human dose for BPC-157 or TB-500. Neither is approved in any market, so there is no label to cite either. That does not make these numbers wrong. It does mean nobody has measured what happens at these levels in humans over time.
Reconstitution sits in the same boat. Dissolving a lyophilised peptide in bacteriostatic water and refrigerating it for weeks is widespread, and no study was found testing the stability, sterility or potency of a self reconstituted research peptide solution at any temperature or duration. Mixing math: peptide reconstitution calculator.
What does the bacteriostatic water label actually say?
It specifies preservative strengths and storage, and assigns no expiry after the vial is first punctured.
The FDA approved Bacteriostatic Water for Injection USP label states benzyl alcohol at 0.9% (9 mg/mL) in the 30 mL plastic vial or 1.1% (11 mg/mL) in the 20 mL glass vial. The preservative permits repeated withdrawals. Storage is 20 to 25 C.
The label states it is indicated only for diluting drugs per the instructions of the drug's manufacturer, and research peptides have no such instructions.
The label was searched for discard, 24 hour and beyond use statements. Zero matches.
The repeated 28 day figure for a punctured vial comes from the Humalog insulin label, and it applies to that product, not the water. More in bacteriostatic versus sterile water.
Does the injection site change how much drug is absorbed?
For healthy tissue the labels say no, and the case for rotation is about preserving tissue rather than chasing better absorption.
The semaglutide and tirzepatide labels state similar exposure was achieved across abdomen, thigh and upper arm, and Wegovy adds that the site can be changed without a dosage modification.
The lipohypertrophy literature answers a different question. A 2026 meta-analysis of 51 studies found incorrect site rotation was the strongest risk factor for lipohypertrophy in insulin users, pooled prevalence odds ratio 8.85 (PMID 40109173). Many authors on that paper declare ties to needle and device manufacturers, and one is an embecta employee. An expert consensus puts prevalence at 29% to 76% and links it to insulin doses up to 25% higher (PMID 42398590) (insulin data, not peptide-specific).
Both are true. Site choice in healthy tissue barely moves exposure. Repeated injection into one spot damages tissue, and absorption becomes unpredictable. Rotation preserves tissue. Mechanics: how to inject peptides. Route question: subcutaneous versus intramuscular.
What about storage and mixing?
Every GLP-1 label caps unrefrigerated storage at 30 C, and one Lilly-authored paper raises a mixing concern for compounded products.
The label figures are product specific: 14 days for Trulicity, up to 56 days for the Ozempic and Wegovy pens, all capped at 30 C (approved label). The full heat picture is on storing peptides in Vietnam heat.
On mixing, testing of compounded tirzepatide combined with vitamin B12 analogues found a previously unidentified impurity formed by a chemical reaction (PMID 42010938). All five authors are Eli Lilly employees, and Lilly makes the approved tirzepatide products these compounded versions compete with. The authors state the impurity's clinical effects are unknown.
What did we check and what did we not find?
Peptides Vietnam checked labels, trials and practice reports; the gaps are findings in themselves.
Three absences matter most. No trial tested the stability of a self reconstituted research peptide solution. The bacteriostatic water label assigns no post-puncture dating. Every technique trial used insulin. Smaller gaps: no evidence on whether cold solution changes injection pain, and no outcome trial on skin disinfection.
Accuracy depends on what is in the vial. Peptara Labs is this site's trusted supply partner, and we may earn from purchases made through our links.
Peptara Labs
peptaralabs.ioWhat we left out
- CDC injection safety guidance: the pages returned access errors.
- USP General Chapter 797: paywalled, not consulted.
- Community figures for research peptides other than BPC-157: none sanctioned without a source.
- A title-only letter on alcohol skin antisepsis: no abstract exists to confirm its finding.
The Short Version
Every approved GLP-1 is a subcutaneous injection into the abdomen, thigh or upper arm.
Semaglutide is the only molecule with both an injection and a tablet, and they are not interchangeable.
Labelled timing is loose: same day each week, any time of day, with or without meals.
Titration exists for stomach tolerability, which the Ozempic label states directly.
Vials plus syringes remove the metered pen. That is the mechanism behind documented ten-fold overdoses.
Nobody has tested how long a self reconstituted research peptide keeps, at any temperature.
Frequently Asked Questions
Is there a best time of day to take a peptide?
For the approved GLP-1 injections the labels say no. Ozempic specifies any time of day, with or without meals, and Wegovy allows changing the time of day without a dosage modification. Oral semaglutide is the strict one: empty stomach, up to 4 ounces of water, 30 minutes before food or other oral medicines.
Do peptides have to be injected?
Almost all of them, yes. Approved GLP-1 labels specify subcutaneous injection because the gut degrades peptide drugs and absorbs them poorly. Semaglutide is the one molecule with an approved tablet, at about 0.4% to 2% oral bioavailability against 89% by injection. The two forms are not substitutable milligram for milligram.
How long does a reconstituted peptide last in the fridge?
Nobody knows. No study was found testing the stability, sterility or potency of a self reconstituted research peptide solution at any temperature or duration. The bacteriostatic water label assigns no post-puncture expiry either. The often quoted 28 day figure comes from the Humalog insulin label.
What is the difference between units and milligrams?
Units describe a syringe scale matched to one product concentration, and milligrams describe mass. On a U-100 syringe, the FDA approved Humalog label puts 100 units at one millilitre, so one unit is 0.01 mL. A poison control case series documented two ten-fold overdoses when compounded semaglutide was described in millilitres, units and milligrams at once.
Why do GLP-1 doses start so low?
The labels state the escalation schedule exists to reduce gastrointestinal adverse reactions. The Ozempic label sets 0.25 mg once weekly for 4 weeks before 0.5 mg, and the Wegovy label titrates every 4 weeks toward 2.4 mg. The starting amount is a tolerability step, not a potency statement.
References
- OZEMPIC (semaglutide) injection, for subcutaneous use. DailyMed Structured Product Label, 2026. FDA approved prescribing information.
- WEGOVY (semaglutide) injection, for subcutaneous use; WEGOVY (semaglutide) tablets, for oral use. DailyMed Structured Product Label, 2026. FDA approved prescribing information.
- MOUNJARO (tirzepatide) injection, for subcutaneous use. DailyMed Structured Product Label, 2026. FDA approved prescribing information.
- TRULICITY (dulaglutide) injection, for subcutaneous use. DailyMed Structured Product Label, 2026. FDA approved prescribing information.
- RYBELSUS (semaglutide) tablets, for oral use; OZEMPIC (semaglutide) tablets, for oral use. DailyMed Structured Product Label, 2026. FDA approved prescribing information.
- HUMALOG (insulin lispro) injection, for subcutaneous or intravenous use. DailyMed Structured Product Label, 2026. FDA approved prescribing information.
- BACTERIOSTATIC WATER for Injection, USP. DailyMed Structured Product Label, 2026. FDA approved prescribing information.
- Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes. Current Medical Research and Opinion, 2010. Randomized controlled trial. (PMID 20429832)
- Administration errors of compounded semaglutide reported to a poison control center: case series. Journal of the American Pharmacists Association, 2023. Case reports. (PMID 37392810)
- Risk factors for lipohypertrophy in people with insulin-treated diabetes: a systematic meta-analysis. Journal of Diabetes Science and Technology, 2026. Meta-analysis. (PMID 40109173)
- Consensus recommendations on lipohypertrophy: insights from an international panel of experts. Diabetes Research and Clinical Practice, 2026. Modified Delphi consensus. (PMID 42398590)
- A novel, widespread impurity in mass-compounded tirzepatide and B12 products: potential patient safety implications. Expert Opinion on Drug Safety, 2026. Analytical chemistry study. (PMID 42010938)
Not medical advice. Consult a healthcare professional before starting any supplement or protocol.
Related Reading
How to Inject Peptides
Sites, angles, and what studies describe
SubQ vs Intramuscular
The route question nobody has trialled
Insulin Syringe Sizes
Unit math and the needle length evidence
Oral vs Injectable Peptides
What swallowing a peptide costs
Storing Peptides in Vietnam Heat
Label ceilings against the real climate
BPC-157 Full Profile
The compound with no approved label anywhere